Highest-materiality recent filing
ANI Pharmaceuticals appoints Henry Gosebruch to board; director Shanmugam resigns
Henry Gosebruch appointed to ANI board effective Aug 19, 2026; term expires at 2027 annual meeting.
ANI Pharma Q2 revenue $266M (+25.9%), GAAP EPS $1.05, adjusted EPS $2.21
Q2 net revenue $266.0M, +25.9% YoY; GAAP net income $24.7M ($1.05/diluted) vs $8.1M prior year.
ANI Pharma stockholders approve Amended 2022 Stock Plan, elect seven directors
Approved Amended 2022 Stock Plan; authorized share reserve increased by 962,000 to 8,222,000 shares.
Company published updated investor presentation on IR website on May 13, 2026.
ANI Pharma Q1 rev $237.5M (+20.5%); raises FY 2026 guidance, authorizes $100M buyback
Q1 net revenue $237.5M (+20.5% YoY); GAAP diluted EPS $1.28; adj non-GAAP diluted EPS $2.05.
ANI Pharmaceuticals dismisses EisnerAmper, appoints Ernst & Young as auditor
EisnerAmper dismissed as independent auditor effective April 1, 2026; Audit Committee approved.
ANI Pharmaceuticals issues investor presentation; no specific updates in filing
Investor presentation provided at Raymond James 47th Annual Institutional Investors Conference on March 3, 2026.
ANI Pharma reports record Q4 revenue $247M, EPS $1.18; reaffirms 2026 guidance
Q4 total net revenue $247.1M (+29.6% YoY); Rare Disease segment $131.3M (+50.8%), Cortrophin Gel $111.4M (+87.6%).
ANI Pharma 2025 rev ~$854-873M, Cortrophin Gel up 76% YoY; 2026 rev target $1.06-1.12B
Full-year 2025 total net revenues expected within or above $854M-$873M guidance ( ~39% YoY growth).
Patrick D. Walsh will not seek re-election as director and steps down as Chairman; no disagreement with board or management.
ANI Pharmaceuticals posts updated investor presentation; no new financials disclosed
Published updated investor presentation on November 10, 2025, available on website.
ANI Pharmaceuticals reports record Q3 2025 revenue and raises full-year guidance
Record quarterly net revenues of $227.8 million, up 53.6% year-over-year.
ANI converts all Series A preferred to common; 602,900 shares issued, preferred eliminated
On Sep 26, 2025, ANI mandatorily converted 20,000 preferred shares into 482,320 common shares at $41.4662/share.
CEO Nikhil Lalwani to present at H.C. Wainwright and Morgan Stanley healthcare conferences on Sep 8-9, 2025.
ANI Pharma Q2 record revenues $211.4M, EPS $0.36; lifts FY guidance
Q2 net revenue $211.4M (+53.1% YoY); GAAP EPS $0.36 vs ($0.14); record adjusted EBITDA $54.1M (+62.8%).
ANI Pharmaceuticals loses jury verdict in royalty dispute with CG Oncology; no damages awarded
Jury returned verdict on July 29, 2025 awarding no damages to ANI on its unjust enrichment counterclaim against CG Oncology.
Preliminary combined ILUVIEN/YUTIQ net revenues for Q2 2025: $22.3M.
ANI Pharma announces NEW DAY clinical trial results; no specifics in filing
Filed Item 8.01 with press release and conference call on NEW DAY Study results.
President & CEO Nikhil Lalwani presented at Jefferies Global Healthcare Conference on June 4, 2025.
ANI shareholders approve doubling authorized common shares to 66M and equity plan amendments
Stockholders approved Certificate of Amendment raising authorized common shares from 33,333,334 to 66,000,000; effective May 22, 2025.
ANI Pharmaceuticals presents at conference; no new material financial disclosure
CEO Nikhil Lalwani presenting at H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025.
ANI Pharma posts record Q1 revenue $197.1M (+43%); raises FY2025 guidance
Record Q1 net revenue $197.1M (+43.4% YoY); Rare Disease $69.0M (Cortrophin Gel $52.9M, +43.1%).
ANI Pharmaceuticals supplements proxy statement on stock plan share reserve
As of March 24, 2025, total stock options outstanding: 571,880 (weighted avg exercise price $46.28, remaining term 3.68 yrs).
ANI Pharmaceuticals buys out perpetual royalty on ILUVIEN/YUTIQ for $17.25M
Paid $17.25M one-time cash to SWK to eliminate 3.125% perpetual royalty on worldwide net revenues of ILUVIEN and YUTIQ.
ANI Pharmaceuticals receives FDA approval to expand ILUVIEN label for chronic non-infectious uveitis
FDA approved ILUVIEN for chronic non-infectious uveitis affecting posterior segment (NIU-PS), expanding beyond DME.
ANI Pharmaceuticals presents at Leerink Partners Global Healthcare Conference on March 11, 2025
CEO Nikhil Lalwani presents at Leerink Partners Global Healthcare Conference in Miami, FL on March 11, 2025.
ANI Pharma Q4 net rev $190.6M (+44.8%), adj EPS $1.63; raises 2025 guidance
Record Q4 net rev $190.6M (+44.8% YoY); organic growth (ex-Alimera) +23.8%.
ANI Pharmaceuticals presents at Guggenheim Biotech Conference; no material news disclosed in filing
Investor presentation furnished as Exhibit 99.1 for Guggenheim Biotech Conference on Feb 5, 2025, but content not provided in this excerpt.
ANI Pharma prelim Q4/FY24 Cortrophin Gel rev $197.8-198.4M; FY25 rev guidance $739-759M
Cortrophin Gel net rev Q4: $59.2-59.8M; FY24: $197.8-198.4M.
ANI Pharmaceuticals presents at Jefferies London; no material updates in limited exhibit text
President & CEO Nikhil Lalwani presented at the 2024 Jefferies London Healthcare Conference on 11/20/2024.
ANI Pharmaceuticals posts record Q3 revenue of $148.3M, raises 2024 guidance
Record quarterly net revenue of $148.3M (+12.5% YoY); Cortrophin Gel revenue $52.6M (+76.8%).
ANI Pharma closes Alimera Sciences acquisition; $5.50/sh cash plus CVRs
Acquisition closed Sept 16, 2024; Alimera shareholders received $5.50 cash per share plus one CVR per share.
Acquired Alimera for $5.50/share plus CVR up to $0.50/share based on 2026-27 net revenue targets; repaid $72.5M Alimera debt.
ANI closes $316.25M convertible notes offering; upsizes due to demand
$316.25M aggregate principal of 2.25% convertible senior notes due 2029 issued; upsized from $250M initial offering.
ANI Pharmaceuticals prices upsized $275M 2.25% convertible notes due 2029
Aggregate principal $275M (upsized from $250M); net proceeds ~$266.8M (or ~$306.8M if full option exercised).
ANI Pharma proposes $250M convertible notes due 2029; to repay term loan
Offering $250M in Convertible Senior Notes due Sept 1, 2029; underwriters option for additional $37.5M.
ANI Pharma Q2 record revenues $138M (+18% YoY); raises FY guidance
Record Q2 net revenues $138.0M (+18.4% YoY); Rare Disease Cortrophin Gel $49.2M (+102.4% YoY).
ANI Pharma to acquire Alimera Sciences for $5.50/share + CVR, funded by $280M debt
Deal consideration: $5.50 cash plus one CVR per Alimera share; adds ~$105M in branded revenue to ANI's rare disease segment.
ANI Pharmaceuticals to present at Jefferies conference; limited filing information available
CEO Nikhil Lalwani will present at the 2024 Jefferies Global Healthcare Conference on June 5, 2024.
ANI Pharmaceuticals shareholders approve Amended 2022 Stock Plan, re-elect directors
At May 21 annual meeting, all eight director nominees elected; Thomas Haughey received 14.8M for, 2.1M against.
ANI Pharmaceuticals CEO presents at investor conference; no financial results disclosed in filing
President & CEO Nikhil Lalwani participated in Capital One Securities Biotech/Biopharma Disruptors Event on May 14, 2024.
ANI Pharmaceuticals Q1 2024: record revenue $137.4M, EPS $0.82; reiterates FY guidance
Q1 net revenue $137.4M (+28.7% YoY); GAAP diluted EPS $0.82 vs $0.06; adjusted non-GAAP EPS $1.21.
ANI Pharmaceuticals provides investor presentation at Piper Sandler symposium; details unavailable
Filing announces CEO Nikhil Lalwani and CFO Stephen Carey meeting investors at Piper Sandler Spring Biopharma Symposium on April 17, 2024.
ANI Pharmaceuticals furnishes investor presentation; no new financial disclosures
Filed updated investor presentation as Exhibit 99.1 dated March 2024.
ANI Pharmaceuticals Q4 revenue up 39.7% YoY; issues 2024 guidance with Cortrophin Gel growth 52-61%
Q4 net revenues $131.7M (+39.7% YoY); GAAP diluted EPS $0.04; adjusted non-GAAP diluted EPS $1.00.
ANI Pharmaceuticals sells former Oakville, ON manufacturing facility for C$19.2M (US$14.2M)
Purchase price C$19.2M (~US$14.2M); buyer paid 5% deposit (~US$710k) with second 5% after due diligence.
ANI Pharmaceuticals to present at Guggenheim Healthcare Talks Biotechnology Conference
CEO Nikhil Lalwani and senior leadership to present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Feb 8, 2024.
ANI Pharmaceuticals updates investor deck at J.P. Morgan Healthcare Conference
Presentation dated January 2024 used in meetings with investors on Jan 8, 2024.
ANI Pharmaceuticals to Present at Jefferies 2023 London Healthcare Conference
President & CEO Nikhil Lalwani will present at the Jefferies 2023 London Healthcare Conference in London, UK on November 15, 2023.
ANI Pharma Q3 revenue $131.8M (+57% YoY); raises FY2023 guidance
Record Q3 net revenue $131.8M, up 57.3% YoY; GAAP net income $9.5M ($0.45 diluted EPS).
On August 22, 2023, Dr. David B. Nash, M.D. informed the Board of his decision not to seek reelection as a director on the Board at the Company’s 2024 Annual Meeting of Stockholders
appointed Matt Leonard to serve on the Board as a director
On March 19, 2022, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) increased the size of the Board from eight to nine members and appointed Renee P. Tannenbaum, Pharm.D., a director of the Company, effective immediately.
On the Closing Date, in connection with the consummation of the Acquisition, the Company announced the appointment of Muthusamy Shanmugam, age 54, as Head of Research & Development and Chief Operating Officer–Novitium Operations.
Max materiality 0.90 · Median 0.55 · Most common event other_material